Cited by 142Psychedelics and Drug StudiesReligion, Spirituality, and PsychologyParanormal Experiences and Beliefs

The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.

5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety

Open access

Davis, Alan K., So, Sara, Lancelotta, Rafael, Barsuglia, Joseph P., Griffiths, Roland R.·2019·The American Journal of Drug and Alcohol Abuse

DOI 10.1080/00952990.2018.1545024PMC PMC6430661

Open this paper in CoChat — free account

Abstract

BACKGROUND: A recent epidemiological study suggested that 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used for spiritual and recreational reasons is associated with subjective improvement in depression and anxiety. Further exploration of the potential psychotherapeutic effects of 5-MeO-DMT could inform future clinical trials. OBJECTIVES: We examined self-reported improvement in depression and anxiety among people who use 5-MeO-DMT in a group setting with structured procedures guiding dose and administration of 5-MeO-DMT. Such procedures also include activities for the preparation of, and support during/following sessions, which are similar to procedures used in clinical trials of hallucinogen administration. Next, we examined whether depression or anxiety were improved following use, and whether the acute subjective effects (mystical/challenging) or beliefs about the 5-MeO-DMT experience were associated with improvements in these conditions. METHODS: = 47.7; Male = 55%; White/Caucasian = 84%) completed an anonymous web-based survey. RESULTS: Of those reporting having been diagnosed with depression (41%) or anxiety (48%), most reported these conditions were improved (depression = 80%; anxiety = 79%) following 5-MeO-DMT use, and fewer reported they were unchanged (depression = 17%; anxiety = 19%) or worsened (depression = 3%; anxiety = 2%). Improvement in depression/anxiety conditions were associated with greater intensity of mystical experiences and higher ratings of the spiritual significance and personal meaning of the 5-MeO-DMT experience. There were no associations between depression or anxiety improvement and the intensity of acute challenging physical/psychological effects during the 5-MeO-DMT experience. CONCLUSIONS: Future prospective controlled clinical pharmacology studies should examine the safety and efficacy of 5-MeO-DMT administration for relieving depression and anxiety.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1080/00952990.2018.1545024

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
What's wrong with Bonferroni adjustments
Perneger, T. V. (1998) · BMJ · doi:10.1136/bmj.316.7139.1236 · Cited by 5,900
The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses
Hofmann, S. G., Asnaani, A., Vonk, I. J. J., Sawyer, A. T., & Fang, A. (2012) · Cognitive Therapy and Research · doi:10.1007/s10608-012-9476-1 · Cited by 3,445
The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013
Steel, Z., Marnane, C., Iranpour, C., Chey, T., Jackson, J. W., Patel, V., & Silove, D. (2014) · International Journal of Epidemiology · doi:10.1093/ije/dyu038 · Cited by 2,846
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 5×
“Three items were also included from the Persisting Effects Questionnaire (24,26,31), in which participants rate the extent to which their first 5-MeO-DMT experience was personally meaningful (on a scale from 0 = “No more than routine, everyday experiences” to 7 = “The single most meaningful experience of my life”), an…”
BackgroundResultInfluentialSelf-citation
Epidemiology of anxiety disorders in the 21st century
Bandelow, B., & Michaelis, S. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.3/bbandelow · Cited by 2,079
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Self-citation
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Self-citation

Show all 43 references

Research works printed but not linked: 6

Center for Behavioral Health Statistics and Quality, 2016, National survey on drug use and health: methodological summary and definitions
10.1002/wps.v13.1 · DOI
10.1177/0269881115622590 · DOI
10.1177/0269881115622590 · DOI
IBM Corp, 2016, IBM SPSS Statistics for Windows, Version 24.0
10.1177/0269881115622590 · DOI

Sorted by citations

Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety
Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.004 · Cited by 375
Self-citation
Cessation and reduction in alcohol consumption and misuse after psychedelic use
Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119845793 · Cited by 225
Self-citation
Long-term effects of psychedelic drugs: A systematic review
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.03.017 · Cited by 279
Self-citation
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms.
Uthaug, M. V., Lancelotta, R., van Oorsouw, K., Kuypers, K. P. C., Mason, N., Rak, J., Šuláková, A., Jurok, R., Maryška, M., Kuchař, M., et al. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05236-w · Cited by 197
Self-citation
Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD
Davis, A. K., Barrett, F. S., So, S., Gukasyan, N., Swift, T. C., & Griffiths, R. R. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120967878 · Cited by 169
Self-citation
Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes
Agin-Liebes, G., Haas, T. F., Lancelotta, R., Uthaug, M. V., Ramaekers, J. G., & Davis, A. K. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00018 · Cited by 124
Self-citation
Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment
Uthaug, M. V., Lancelotta, R., Szabo, A., Davis, A. K., Riba, J., & Ramaekers, J. G. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05414-w · Cited by 117
“Nevertheless, from a recent survey among users in the general population, it appears that 5-MeO-DMT has an acceptable physiological safety profile in naturalistic settings (Davis et al. 2018; Davis et al. 2019), as well as a low addiction liability (Davis et al. 2018).”
BackgroundResultInfluentialSelf-citation
The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT)
Reckweg, J. T., Uthaug, M. V., Szabó, A., Davis, A. K., Lancelotta, R., Mason, N. L., & Ramaekers, J. G. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15587 · Cited by 126
Self-citation
Post-Psychedelic Reductions in Experiential Avoidance Are Associated With Decreases in Depression Severity and Suicidal Ideation
Zeifman, R. J., Wagner, A. C., Watts, R., Kettner, H., Mertens, L. J., & Carhart-Harris, R. L. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00782 · Cited by 106
“Additionally, Davis et al. (18) found that decreased AAQ-II scores indirectly affected the relationship between acute psychedelic experiences (mystical-type experiences and psychological insight) and decreases in anxiety and depression severity.”
Background
Association between mystical-type experiences under psychedelics and improvements in well-being or mental health – A comprehensive review of the evidence
Kangaslampi, S. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00243 · Cited by 111
People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences
Williams, M. T., Davis, A. K., Xin, Y., Sepeda, N. D., Grigas, P. C., Sinnott, S., & Haeny, A. M. (2021) · Drugs: Education, Prevention and Policy · doi:10.1080/09687637.2020.1854688 · Cited by 101
Self-citation
A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression
Reckweg, J. T., van Leeuwen, C. J., Henquet, C., van Amelsvoort, T., Theunissen, E. L., Mason, N. L., Paci, R., Terwey, T. H., & Ramaekers, J. G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1133414 · Cited by 96
Identification of Psychoplastogenic N , N -Dimethylaminoisotryptamine (isoDMT) Analogues through Structure–Activity Relationship Studies
Dunlap, L. E., Azinfar, A., Ly, C., Cameron, L. P., Viswanathan, J., Tombari, R. J., Myers-Turnbull, D., Taylor, J. C., Grodzki, A. C., Lein, P. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01404 · Cited by 95
A narrative synthesis of research with 5-MeO-DMT
Ermakova, A. O., Dunbar, F., Rucker, J., & Johnson, M. W. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211050543 · Cited by 94
Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans
Davis, A. K., Averill, L. A., Sepeda, N. D., Barsuglia, J. P., & Amoroso, T. (2020) · Chronic Stress · doi:10.1177/2470547020939564 · Cited by 87
Self-citation
Novel antidepressant drugs: Beyond monoamine targets
Gonda, X., Döme, P., Neill, J. C., & Tarazi, F. I. (2021) · CNS Spectrums · doi:10.1017/s1092852921000791 · Cited by 83
Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study
Barsuglia, J. P., Davis, A. K., Palmer, R. L., Lancelotta, R., Windham-Herman, A.-M., Peterson, K., Polanco, M., Grant, R., & Griffiths, R. R. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.02459 · Cited by 90
Self-citation
Structural pharmacology and therapeutic potential of 5-methoxytryptamines
Warren, A. L., Lankri, D., Cunningham, M. J., Serrano, I. C., Parise, L. F., Kruegel, A. C., Duggan, P., Zilberg, G., Capper, M. J., Havel, V., et al. (2024) · Nature · doi:10.1038/s41586-024-07403-2 · Cited by 84
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample
Nygart, V. A., Pommerencke, L. M., Haijen, E. C. H. M., Kettner, H., Kaelen, M., Mortensen, E. L., Nutt, D. J., Carhart-Harris, R. L., & Erritzøe, D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221101061 · Cited by 79
Increases in Psychological Flexibility Mediate Relationship Between Acute Psychedelic Effects and Decreases in Racial Trauma Symptoms Among People of Color
Davis, A. K., Xin, Y., Sepeda, N. D., Garcia-Romeu, A., & Williams, M. T. (2021) · Chronic Stress · doi:10.1177/24705470211035607 · Cited by 67
Self-citation
The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects
Uthaug, M. V., Davis, A. K., Haas, T. F., Davis, D. D., Dolan, S. B., Lancelotta, R., Timmermann, C., & Ramaekers, J. G. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211013583 · Cited by 71
Self-citation
A unified model of ketamine’s dissociative and psychedelic properties
Marguilho, M., Figueiredo, I., & Castro-Rodrigues, P. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221140011 · Cited by 71
2019: A year of expansion in psychedelic research, industry, and deregulation
Aday, J. S., Bloesch, E. K., & Davoli, C. C. (2020) · Drug Science Policy and Law · doi:10.1177/2050324520974484 · Cited by 60
5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice
Jefferson, S. J., Gregg, I., Dibbs, M., Liao, C., Wu, H., Davoudian, P. A., Woodburn, S. C., Wehrle, P. H., Sprouse, J. S., Sherwood, A. M., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01572-w · Cited by 57
A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers
Reckweg, J., Mason, N. L., van Leeuwen, C., Toennes, S. W., Terwey, T. H., & Ramaekers, J. G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.760671 · Cited by 58
Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders
Lowe, H. I. C., Toyang, N. J., Steele, B., Grant, J., Ali, A., Gordon, L., & Ngwa, W. F. (2022) · Molecules · doi:10.3390/molecules27082520 · Cited by 58
The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis
Roméo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Bezo, A., Piolino, P., & Benyamina, A. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106086 · Cited by 53
Psychedelics and potential benefits in “healthy normals”: A review of the literature
Gandy, S. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.029 · Cited by 52
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
Mastinu, A., Anyanwu, M., Carone, M., Abate, G., Bonini, S. A., Peron, G., Tirelli, E., Pucci, M., Ribaudo, G., Oselladore, E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021329 · Cited by 52
Effects of DMT on mental health outcomes in healthy volunteers
Timmermann, C., Zeifman, R. J., Erritzøe, D., Nutt, D., & Carhart-Harris, R. L. (2024) · Scientific Reports · doi:10.1038/s41598-024-53363-y · Cited by 48
Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy- N,N -dimethyltryptamine benzoate) in healthy participants
Rucker, J., Roberts, C., Seynaeve, M., Young, A. H., Suttle, B., Yamamoto, T., Ermakova, A. O., Dunbar, F., & Wiegand, F. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241246857 · Cited by 47
N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine
James, E., Keppler, J., Robertshaw, T. L., & Sessa, B. (2022) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2835 · Cited by 50
Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use
Sherwood, A. M., Claveau, R., Lancelotta, R., Kaylo, K. W., & Lenoch, K. (2020) · ACS Omega · doi:10.1021/acsomega.0c05099 · Cited by 38
Self-citation
Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis
Dourron, H. M., Strauss, C. K., & Hendricks, P. S. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000514 · Cited by 35
Nutmegs and wild nutmegs: An update on ethnomedicines, phytochemicals, pharmacology, and toxicity of the Myristicaceae species
Barman, R., Bora, P. K., Saikia, J., Kemprai, P., Saikia, S. P., Haldar, S., & Banik, D. (2021) · Phytotherapy Research · doi:10.1002/ptr.7098 · Cited by 35
Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics
Hovmand, O. R., Poulsen, E. D., & Arnfred, S. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811231200019 · Cited by 33
“…psilocybin (Bogenschutz et al., 2015; Garcia-Romeu et al., 2014; Griffiths et al., 2008; Roseman et al., 2018) but also a variety of psychedelic sub-stances including DMT (Barsuglia et al., 2018; Bouso et al., 2016; Davis et al., 2019) and LSD (Liechti et al., 2017; Schmid and Liechti, 2018).”
Background
Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects
Lancelotta, R. L., & Davis, A. K. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1737763 · Cited by 33
Self-citation
Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland
Kangaslampi, S., Hausen, A., & Rauteenmaa, T. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1767321 · Cited by 31
The Altered States Database: Psychometric data from a systematic literature review
Prugger, J., Derdiyok, E., Dinkelacker, J., Costines, C., & Schmidt, T. T. (2022) · Scientific Data · doi:10.1038/s41597-022-01822-4 · Cited by 36
5-HT2A SNPs Alter the Pharmacological Signaling of Potentially Therapeutic Psychedelics
Schmitz, G. P., Jain, M. K., Slocum, S. T., & Roth, B. L. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00815 · Cited by 29
Psychotherapeutic and neurobiological processes associated with ayahuasca: A proposed model and implications for therapeutic use
Perkins, D., Ruffell, S., Day, K., Rubiano, D. P., & Sarris, J. J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.879221 · Cited by 33
Anxiety-like behavior induced by salicylate depends on age and can be prevented by a single dose of 5-MeO-DMT
Winne, J., Ciralli, B., Malfatti, T., Brisa, E., Doerl, J. G., Nogueira, I., Leão, K. E., & Leão, R. N. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113175 · Cited by 27
5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?
Dourron, H. M., Nichols, C. D., Simonsson, O., Bradley, M. K., Carhart-Harris, R. L., & Hendricks, P. S. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06517-1 · Cited by 36
Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence
Bernal, A. M. O., Raison, C. L., Lancelotta, R., & Davis, A. K. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1049643 · Cited by 32
Self-citation
Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms
Nikolaidis, A., Lancelotta, R., Gukasyan, N., Griffiths, R. R., Barrett, F. S., & Davis, A. K. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.12.042 · Cited by 26
Self-citation
“In vivo biosynthesis of N,N-dimethyltryptamine, 5-MeO-N,N-dimethyltryptamine, and bufotenine in E. coli”
Friedberg, L. M., Sen, A. K., Nguyen, Q., Tonucci, G. P., Hellwarth, E. B., Gibbons, W. J., & Jones, J. A. (2023) · Metabolic Engineering · doi:10.1016/j.ymben.2023.05.006 · Cited by 27
A comparison of reactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting
Uthaug, M. V., Lancelotta, R., Bernal, A. M. O., Davis, A. K., & Ramaekers, J. G. (2020) · Journal of Psychedelic Studies · doi:10.1556/2054.2020.00123 · Cited by 25
Self-citation
Psilocybin for major depressive disorder: a systematic review of randomized controlled studies
Li, L., Mo, Y., Shi, Z.-M., Huang, X., Ning, Y.-P., Wu, H., Yang, X.-H., & Zheng, W. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1416420 · Cited by 28
Predictors and potentiators of psychedelic-occasioned mystical experiences
Gandy, S. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00198 · Cited by 32
Inhaled 5-methoxy-N,N-dimethyltryptamine: Supportive context associated with positive acute and enduring effects
Sepeda, N. D., Clifton, J. M., Doyle, L. Y., Lancelotta, R., Griffiths, R. R., & Davis, A. K. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.033 · Cited by 26
Self-citation
Classification of psychedelics and psychoactive drugs based on brain-wide imaging of cellular c-Fos expression
Aboharb, F., Davoudian, P. A., Shao, L.-X., Liao, C., Rzepka, G. N., Wojtasiewicz, C., Indajang, J., Dibbs, M., Rondeau, J. A., Sherwood, A. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56850-6 · Cited by 24
Hallucinogenic drugs and their potential for treating fear‐related disorders: Through the lens of fear extinction
Glavonic, E., Mitić, M., & Adžić, M. (2022) · Journal of Neuroscience Research · doi:10.1002/jnr.25017 · Cited by 21
This is your brain on death: a comparative analysis of a near-death experience and subsequent 5-Methoxy-DMT experience
Michael, P., Luke, D. P., & Robinson, O. C. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1083361 · Cited by 24
Serotonergic psychedelic 5-MeO-DMT alters plasticity-related gene expression and generates anxiolytic effects in stressed mice
Nogueira, M., Golbert, D. C. F., de Menezes, R. S. T., de Almeida, R. N., Coelho, N. L. G., Siroky, A. N., Lima, T. Z., Maia, H., Leão, K. E., & Leão, R. N. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02655-w · Cited by 22
Psychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among United States Special Operations Forces Veterans
Mangini, P., Averill, L. A., & Davis, A. K. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00176 · Cited by 19
Self-citation
Exploring the Use of Psilocybin Therapy for Existential Distress: A Qualitative Study of Palliative Care Provider Perceptions
Mayer, C. E., LeBaron, V. T., & Acquaviva, K. (2021) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.1916659 · Cited by 18
Vitiligo and Mental Health: Natural Compounds’ Usefulness
Bartolomeo, L. D., Custurone, P., Irrera, N., Borgia, F., Vaccaro, F., Squadrito, F., & Vaccaro, M. (2023) · Antioxidants · doi:10.3390/antiox12010176 · Cited by 18
5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study
Ragnhildstveit, A., Khan, R., Seli, P., Bass, L. C., August, R. J., Kaiyo, M., Barr, N., Jackson, L. K., Gaffrey, M. S., Barsuglia, J. P., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1271152 · Cited by 24
Self-citation
The potential of 5‐methoxy‐ N,N ‐dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action
Tap, S. C. (2024) · Addiction Biology · doi:10.1111/adb.13386 · Cited by 16
‘Mind-Revealing’ Psychedelic States: Psychological Processes in Subjective Experiences That Drive Positive Change
Walther, R. F. E., & van Schie, H. T. (2024) · Psychoactives · doi:10.3390/psychoactives3030026 · Cited by 20
Key Characteristics and Development of Psychoceuticals: A Review
Cano, G. E. H., Dean, J., Abreu, S. P., Rodríguez, A. H., Abbasi, C., Hinson, M., & Lucke-Wold, B. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415777 · Cited by 14
Psychedelics, epilepsy, and seizures: a review
Freidel, N., Kreuder, L., Rabinovitch, B. S., Chen, F. Y., Huang, R. S., & Lewis, E. C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1326815 · Cited by 14
Serotonin 1A Receptors Modulate Serotonin 2A Receptor-Mediated Behavioral Effects of 5-Methoxy- N , N -dimethyltryptamine Analogs in Mice
Glatfelter, G. C., Clark, A. A., Cavalco, N. G., Landavazo, A., Partilla, J. S., Naeem, M., Golen, J. A., Chadeayne, A. R., Manke, D. R., Blough, B. E., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00513 · Cited by 15
Qualitative and Quantitative Analysis of Tryptamines in the Poison of Incilius alvarius (Amphibia: Bufonidae)
Schwelm, H. M., Zimmermann, N., Scholl, T., Penner, J., Autret, A., Auwärter, V., & Neukamm, M. A. (2021) · Journal of Analytical Toxicology · doi:10.1093/jat/bkab038 · Cited by 13
Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study
Hartong, V., & van Emmerik, A. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2080616 · Cited by 11
“***p < .001. multiple domains including attitudes, prosocial behavior, depression, anxiety and satisfaction with life in healthy individuals (Davis et al. 2019; Griffiths et al. 2018, 2011; Uthaug et al. 2019).”
Background
Pharmacological Monotherapy for Depressive Disorders: Current and Future—A Narrative Review
Gao, K., Oruc, E. B., & Koparal, B. (2025) · Medicina · doi:10.3390/medicina61040558 · Cited by 13
Quantum chemical (QM:MM) investigation of the mechanism of enzymatic reaction of tryptamine and N , N -dimethyltryptamine with monoamine oxidase A
Kubicskó, K., & Farkas, Ö. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob01118e · Cited by 12
Associations between the use of psychedelics and other recreational drugs with mental health and resilience during the COVID-19 pandemic
Bălăeţ, M., Trender, W. R., Hellyer, P. J., & Hampshire, A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1184681 · Cited by 13
The possible place for psychedelics in pharmacotherapy of mental disorders
Wojtas, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00550-9 · Cited by 12
Recent Evidence on the Antidepressant Effects of Ayahuasca
Palhano-Fontes, F., Mota-Rolim, S. A., Soares, B. L., Coelho, N. L. G., Maia‐de‐Oliveira, J. P., & de Araújo, D. B. (2021) · Springer eBooks · doi:10.1007/978-3-030-55688-4_2 · Cited by 12
Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa
Rodan, S.-C., Aouad, P., McGregor, I. S., & Maguire, S. (2021) · OBM Neurobiology · doi:10.21926/obm.neurobiol.2102102 · Cited by 12
Hypothetical biosynthetic pathways of pharmaceutically potential hallucinogenic metabolites in Myristicaceae, mechanistic convergence and co-evolutionary trends in plants and humans
Barman, R., Bora, P. K., Saikia, J., Konwar, P., Sarkar, A., Kemprai, P., Saikia, S. P., Haldar, S., Slater, R. J., & Banik, D. (2023) · Phytochemistry · doi:10.1016/j.phytochem.2023.113928 · Cited by 9
Acute subjective effects of psychedelics in naturalistic group settings prospectively predict longitudinal improvements in trauma symptoms, trait shame, and connectedness among adults with childhood maltreatment histories
Healy, C. J., Frazier, A., Kirsch, S., Sanford, A., Garcia‐Romeu, A., Todman, M., Varon, J. P., & D'Andrea, W. M. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111361 · Cited by 9
A Scoping Review of Research in Naturalistic Studies with Psychedelics
de Carvalho, L. L., Encantado, J., Kettner, H., Timmermann, C., Veiga, D., & Teixeira, P. J. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2520221 · Cited by 10
EMBARK Psychedelic Therapy for Depression
Brennan, B., & Belser, A. (2024) · doi:10.1093/9780197762622.001.0001 · Cited by 8
Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study
Millón, M. B. B., Noguera, L., Bruno, D., Vita, L., Zanino, M., Kassuha, D., Ortiz, J. E., Feresin, G. E., Díaz-Dellavalle, P., Orosco, L. L., et al. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02167-3 · Cited by 7
Systems-level analysis of local field potentials reveals differential effects of lysergic acid diethylamide and ketamine on neuronal activity and functional connectivity
Nasretdinov, A., Barrientos, S. A., Brys, I., Halje, P., & Petersson, P. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1175575 · Cited by 7
New Insights Into the Clinical and Nonclinical Effects of Psychedelic Substances
Forstmann, M., & Sagioglou, C. (2021) · European Psychologist · doi:10.1027/1016-9040/a000447 · Cited by 7
3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs
López‐Arnau, R., Camarasa, J., Carbó, M., Nadal‐Gratacós, N., Puigseslloses, P., Espinosa‐Velasco, M., Urquizu, E., Escubedo, E., & Pubill, D. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.990405 · Cited by 6
Infoveillance and Critical Analysis of the Systematically Reviewed Literature on Dimethyltryptamine and the “God Molecule”
Al-Imam, A., Motyka, M. A., Hoffmann, B., Magowska, A. M., & Michalak, M. (2023) · Pharmaceuticals · doi:10.3390/ph16060831 · Cited by 6
Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury
Plummer, Z., Allen, J., Brand, J., Mayo, L. M., Shultz, S. R., & Christie, B. R. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111448 · Cited by 6
Predictors of therapeutic response to psychedelic-assisted therapy: A systematic review
Viljoen, G., Walter, H., Bendau, A., Koslowski, M., & Betzler, F. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251389581 · Cited by 8
On the advances in machine learning and complex network measures to an EEG dataset from DMT experiments
Alves, C. L., Ciba, M., Toutain, T. G. L. D. O., Porto, J. A. M., de Sena, E. P., Thielemann, C., & Rodrigues, F. A. (2024) · Journal of Physics Complexity · doi:10.1088/2632-072x/ad1c68 · Cited by 4
On the social epistemology of psychedelic experience
Pedersen, M. M., & Steglich‐Petersen, A. (2024) · Philosophical Psychology · doi:10.1080/09515089.2024.2369685 · Cited by 6
Unveiling Psychedelics: One of the Most Meaningful Events in Life Associated with Improved Well-Being in Swedish Users
Kajonius, P., Sjöström, D., & Claesdotter‐Knutsson, E. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2444892 · Cited by 8
Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and Potential Harms
Tariq, R. (2022) · Current Clinical Pharmacology · doi:10.2174/2772432817666220321142707 · Cited by 5
Toad in the road: Biocultural history and conservation challenges of the Sonoran Desert Toad
Villa, R. A. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00269 · Cited by 5
Continuous flow synthesis of N , N -dimethyltryptamine (DMT) analogues with therapeutic potential
Simoens, A., Dejaegere, A., Vandevelde, M., & Stevens, C. V. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00562g · Cited by 5
Pharmacological Properties of Psychedelics with a Special Focus on Potential Harms
Holze, F., Liechti, M. E., & Müller, F. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_510 · Cited by 5
Bufotenidinium iodide
Pham, D. N. K., Chadeayne, A. R., Golen, J. A., & Manke, D. R. (2021) · IUCrData · doi:10.1107/s2414314621001231 · Cited by 4
From molecules to meaning: unpacking the antidepressant mechanisms of psychedelic drugs
Acero, V. P., Flatt, T. A., Gooch, P. M., Gaughan, S. J., Levin, A. W., & Davis, A. K. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2515866 · Cited by 4
Self-citation
The transformational power of psychedelics: catalysts for creativity, consciousness, and mental health
Du, X., Liu, J., & Wang, X. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03291-8 · Cited by 3
A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy- N,N -dimethyltryptamine) in patients with treatment-resistant depression
Roberts, C., Seynaeve, M., Ermakova, A. O., Dunbar, F., Wells, H., Puri, A., Bird, C., & Rucker, J. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261420087 · Cited by 6
Beyond prohibition: A public health analysis of naturalistic psychedelic use
Haden, M., Paschall, S. A., & Woods, B. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00450 · Cited by 3
L'anxiété et la dépression liées à la fin de vie soulagées par psychothérapie assistée de psychédéliques
Carrigan, K., FRANÇOIS, M., Dubus, Z., & Fauvel, B. (2022) · Revue Education Santé Sociétés · doi:10.17184/eac.6033 · Cited by 3
With great power comes great responsibility: Promise and caution in the new psychedelic renaissance
Halma, M. T. J., Levy, R., & Varón, J. (2025) · Brain Disorders · doi:10.1016/j.dscb.2025.100286 · Cited by 2
Reactivations Associated with the Use of 5-MeO-DMT Among Spanish-Speaking Individuals: Prevalence, Predictors, and Emotional Valence
Bernal, A. M. O., Raison, C. L., Lancelotta, R., Timmermann, C., Sepeda, N. D., & Davis, A. K. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2577305 · Cited by 1
Self-citation
Bufotenidine attenuates astrocyte ferroptosis in depressive-like behaviors through targeting GluA1 to reduce neuronal lipid synthesis
Wu, W., Chen, Z., Xu, Y., Xie, X., Tan, A., Hu, M., Xu, D., Lv, X., Chen, W., Zhou, J., et al. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.03.024 · Cited by 2
Mimosa tenuiflora (Willd.) Poir e Anadenanthera colubrina como alternativas no tratamento da adicção às drogas
de Sousa, P. C. M., de Sousa, I. N. A., Leite, L. L. L., Oliveira, A. L. O., Souza, K. A. D. S., Soares, J. D. S., Viana, M. D. R., & do Amaral, M. P. D. M. (2021) · Research Society and Development · doi:10.33448/rsd-v10i4.14251 · Cited by 3

Authors: Davis, A. K., So, S., Lancelotta, R., Barsuglia, J. P., & Griffiths, R. R.
Affiliations: Johns Hopkins University (US)
University of Wyoming (US)
New School Research, LLC, North Hollywood, CA, USA
Corresponding author: Davis, Alan K.
ORCID: Davis, Alan K.
Lancelotta, Rafael
Barsuglia, Joseph P.
Griffiths, Roland R.
Venue: The American Journal of Drug and Alcohol Abuse
Publisher: Informa UK Limited
Published: 2019-03-01
Volume: 45
Issue: 2
Pages: 161-169
ISSN: 0095-2990 (ISSN-L)
1097-9891
DOI: 10.1080/00952990.2018.1545024
PMC: PMC6430661
OpenAlex: W2919995896
Cited by: 142
References: 43
Citations by year: 2026: 15 · 2025: 19 · 2024: 29 · 2023: 21 · 2022: 20 · 2021: 17 · 2020: 13 · 2019: 7
FWCI: 16.64
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: The American Journal of Drug and Alcohol Abuse (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute on Alcohol Abuse and Alcoholism (AA007747)
National Institute on Drug Abuse (DA003889, DA007209)
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Social Sciences › Health › Religion, Spirituality, and Psychology
Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
Keywords: 5-MeO-DMT, depression, anxiety, psychedelics, mystical experience, challenging experiences, spiritual meaning, group settings, recreational drug use, subjective improvement, hallucinogens
MeSH terms: Adult, Depressive Disorder, Female, Hallucinogens, Humans, Male, Methoxydimethyltryptamines, Middle Aged, Psychometrics, Surveys and Questionnaires, Internet, Self Report

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks